MiR-21 Is Required for the Epithelial-Mesenchymal Transition in MDA-MB-231 Breast Cancer Cells

dc.contributor.authorArisan, Elif Damla
dc.contributor.authorRencuzogullari, Ozge
dc.contributor.authorCieza-Borrella, Clara
dc.contributor.authorMiralles Arenas, Francesc
dc.contributor.authorDwek, Miriam
dc.contributor.authorLange, Sigrun
dc.contributor.authorUysal-Onganer, Pinar
dc.date.accessioned2025-10-29T11:08:55Z
dc.date.issued2021
dc.departmentEnstitüler, Lisansüstü Eğitim Enstitüsü, Biyomühendislik Ana Bilim Dalı
dc.description.abstractBreast cancer (BCa) is one of the leading health problems among women. Although significant achievements have led to advanced therapeutic success with targeted therapy options, more efforts are required for different subtypes of tumors and according to genomic, transcriptomic, and proteomic alterations. This study underlines the role of microRNA-21 (miR-21) in metastatic MDA-MB-231 breast cancer cells. Following the knockout of miR-21 from MDA-MB-231 cells, which have the highest miR-21 expression levels compared to MCF-7 and SK-BR-3 BCa cells, a decrease in epithelial-mesenchymal transition (EMT) via downregulation of mesenchymal markers was observed. Wnt-11 was a critical target for miR-21, and the Wnt-11 related signaling axis was altered in the stable miR-21 knockout cells. miR-21 expression was associated with a significant increase in mesenchymal markers in MDA-MB-231 BCa cells. Furthermore, the release of extracellular vesicles (EVs) was significantly reduced in the miR-21 KO cells, alongside a significant reduction in relative miR-21 export in EV cargo, compared with control cells. We conclude that miR-21 is a leading factor involved in mesenchymal transition in MDA-MB-231 BCa. Future therapeutic strategies could focus on its role in the treatment of metastatic breast cancer.
dc.description.sponsorshipUniversity of Westminster [CB515115]
dc.description.sponsorshipWe are thankful for the partial support from the University of Westminster Startup Grant CB515115 to Pinar Uysal-Onganer.
dc.identifier.doi10.3390/ijms22041557
dc.identifier.issn1661-6596
dc.identifier.issn1422-0067
dc.identifier.issue4
dc.identifier.orcid0000-0002-7193-3102
dc.identifier.orcid0000-0003-3190-8831
dc.identifier.orcid0000-0003-2739-1040
dc.identifier.orcid0000-0003-3069-2725
dc.identifier.orcid0000-0002-2157-1289
dc.identifier.orcid0000-0002-4844-6381
dc.identifier.pmid33557112
dc.identifier.scopus2-s2.0-85100344018
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3390/ijms22041557
dc.identifier.urihttps://hdl.handle.net/20.500.14854/5574
dc.identifier.volume22
dc.identifier.wosWOS:000623761800001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofInternational Journal of Molecular Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20251020
dc.subjectbreast cancer
dc.subjectmiR-21
dc.subjectWnt-11
dc.subjectEMT
dc.titleMiR-21 Is Required for the Epithelial-Mesenchymal Transition in MDA-MB-231 Breast Cancer Cells
dc.typeArticle

Dosyalar